Patents Assigned to ONO Pharmaceutical Co., Ltd.
  • Publication number: 20210371379
    Abstract: 4-({(4S)-1-(4-Carbamimidoylbenzoyl)-4-[4-(methylsulfonyl)piperazin-1-yl]-L-prolyl}amino) benzoic acid di(4-toluenesulfonate) or dibenzenesulfonate or their crystal forms can be useful pharmaceutical ingredients because of their low hygroscopicity and excellent storage stability.
    Type: Application
    Filed: September 19, 2019
    Publication date: December 2, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Taihei NISHIYAMA, Takahiro NEKADO
  • Publication number: 20210363166
    Abstract: A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.
    Type: Application
    Filed: August 6, 2021
    Publication date: November 25, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Ryosuke HANADA, Masaya KOKUBO, Masakuni KURONO, Kenichi KOUDA, Hiroshi HAGIYA
  • Publication number: 20210347773
    Abstract: Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.
    Type: Application
    Filed: May 24, 2021
    Publication date: November 11, 2021
    Applicants: ONO PHARMACEUTICAL CO., LTD., VANDERBILT UNIVERSITY
    Inventors: Craig W. LINDSLEY, Joshua M. WIETING, Kevin M. MCGOWAN, Jerod S. DENTON, Kentaro YASHIRO, Haruto KURATA, Yoko SEKIOKA, Takahiro MORI, Yuzo IWAKI
  • Publication number: 20210332134
    Abstract: A bispecific antibody which is capable of specifically binding to PD-1 and CD3 is disclosed. The bispecific antibody is suitable for preventing, suppressing symptom progression or recurrence of, and/or treating autoimmune diseases. Also disclosed is a formulation which can reduce occurrence of adverse infusion reactions or adverse reaction called cytokine release syndrome. The bispecific antibody has the feature to allow interaction between PD-1 and PD-L1 as its ligand, contributes enhancement or duration of its effects.
    Type: Application
    Filed: July 2, 2021
    Publication date: October 28, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shiro SHIBAYAMA, Takuya SHIMBO, Tomoya TEZUKA, Mark THROSBY, Cornelis Adriaan de KRUIF, Pieter Fokko van LOO, Rinse KLOOSTER
  • Publication number: 20210332009
    Abstract: A compound represented by general formula (I) (in the formula, all symbols are as described in the description) or a salt thereof has a potent nerve-protecting and/or -repairing activity, and therefore can be used as a therapeutic agent for neuropathy (e.g., chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, periarteritis nodosa, allergic vasculitis, diabetic peripheral neuropathy, entrapment neuropathy, peripheral neuropathy associated with the administration of a chemotherapeutic drug, or peripheral neuropathy associated with Charcot-Marie-Tooth disease).
    Type: Application
    Filed: July 30, 2019
    Publication date: October 28, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shoji NOJIMA, Kenji SASAKI, Tohru KAMBE, Takashi KONEMURA, Yoshikazu GOTO
  • Patent number: 11130773
    Abstract: A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: September 28, 2021
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Ryosuke Hanada, Masaya Kokubo, Masakuni Kurono, Kenichi Kouda, Hiroshi Hagiya
  • Publication number: 20210253615
    Abstract: A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.
    Type: Application
    Filed: October 10, 2019
    Publication date: August 19, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Ryosuke HANADA, Masaya KOKUBO, Masakuni KURONO, Kenichi KOUDA, Hiroshi HAGIYA
  • Patent number: 11091550
    Abstract: A bispecific antibody which is capable of specifically binding to PD-1 and CD3 is disclosed. The bispecific antibody is suitable for preventing, suppressing symptom progression or recurrence of, and/or treating autoimmune diseases. Also disclosed is a formulation which can reduce occurrence of adverse infusion reactions or adverse reaction called cytokine release syndrome. The bispecific antibody has the feature to allow interaction between PD-1 and PD-L1 as its ligand, contributes enhancement or duration of its effects.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: August 17, 2021
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shiro Shibayama, Takuya Shimbo, Tomoya Tezuka, Mark Throsby, Cornelis Adriaan de Kruif, Pieter Fokko van Loo, Rinse Klooster
  • Publication number: 20210222177
    Abstract: An object of the present disclosure is to provide a novel therapeutic agent for a cartilage-related disease, having cartilage regenerating action. Since a substance having SIK2 inhibitory action has chondrocyte differentiation promoting action, a therapeutic agent containing a substance having SIK2 inhibitory action is useful as a therapeutic agent having cartilage regenerating action for cartilage-related diseases such as cartilage damage or osteoarthritis.
    Type: Application
    Filed: July 31, 2019
    Publication date: July 22, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Yuki TSUMORI, Yasutomo NAKANISHI, Shinsei FUJIMURA
  • Patent number: 11065226
    Abstract: A medicament comprising a combination of a compound represented by formula (I), a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these and an immune checkpoint inhibitor (such as an anti-PD-1 antibody), which exhibits a strong anti-tumor effect and thus is useful for the treatment of cancer.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: July 20, 2021
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Takao Yoshida, Akiko Shoyama, Hirotsugu Takano
  • Publication number: 20210214441
    Abstract: A bispecific antibody which is capable of specifically binding to PD-1 and CD3 is disclosed. The bispecific antibody is suitable for preventing, suppressing symptom progression or recurrence of, and/or treating autoimmune diseases. Also disclosed is a formulation which can reduce occurrence of adverse infusion reactions or adverse reaction called cytokine release syndrome. The bispecific antibody has the feature to allow interaction between PD-1 and PD-L1 as its ligand, contributes enhancement or duration of its effects.
    Type: Application
    Filed: February 8, 2019
    Publication date: July 15, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shiro SHIBAYAMA, Takuya SHIMBO, Tomoya TEZUKA, Mark THROSBY, Cornelis Adriaan de KRUIF, Pieter Fokko van LOO, Rinse KLOOSTER
  • Patent number: 11052091
    Abstract: The present invention relates to a Brk inhibitory compound represented by general formula (I) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug of any of these.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: July 6, 2021
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo Yamamoto, Masakuni Kurono, Atsushi Yoshida, Shingo Hotta
  • Publication number: 20210198361
    Abstract: The object of the present invention is to provide a method for identifying a patient with malignant tumor on which the effect of an immune checkpoint inhibitor can be more expected, and agents for suppressing the progression of, suppressing the recurrence of, and/or treating malignant tumor, characterized by prescriptions based on those. The present invention can provide agents for suppressing the progression of, suppressing the recurrence of, and/or treating malignant tumor, characterized by prescriptions based on identifying a patient with a malignant tumor on which the effect of an immune checkpoint inhibitor can be more expected, by analyzing the evaluation items consisting of combinations such as the PD-1 expression intensity, the percentage of the number of PD-1 expressing cells and the like in Treg cells and CD8+ T cells in tumor tissue or blood.
    Type: Application
    Filed: May 30, 2019
    Publication date: July 1, 2021
    Applicants: ONO PHARMACEUTICAL CO., LTD., NATIONAL CANCER CENTER
    Inventors: Hiroyoshi NISHIKAWA, Yosuke TOGASHI, Yukiya OHYAMA, Takao YOSHIDA, Kazuhiko TAKEDA, Kenichi KODA, Atsushi HONDA, Atsushi OYAGI, Toru KAKINUMA, Masayuki MURATA
  • Patent number: 11046683
    Abstract: Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: June 29, 2021
    Assignees: ONO PHARMACEUTICAL CO., LTD., VANDERBILT UNIVERSITY
    Inventors: Craig W Lindsley, Joshua M. Wieting, Kevin M. McGowan, Jerod S. Denton, Kentaro Yashiro, Haruto Kurata, Yoko Sekioka, Takahiro Mori, Yuzo Iwaki
  • Publication number: 20210169842
    Abstract: Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
    Type: Application
    Filed: January 14, 2021
    Publication date: June 10, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tohru KAMBE, Toru MARUYAMA, Shinsaku YAMANE, Satoshi NAKAYAMA, Kousuke TANI
  • Publication number: 20210163466
    Abstract: A compound represented by general formula (I): (wherein in the formula, all the symbols have the same meanings as those described in the specification), or a pharmaceutically acceptable salt thereof is useful as a medicament's active ingredient having an EP4 receptor antagonistic activity, in preventing and/or treating disease caused by activation of an EP4 receptor.
    Type: Application
    Filed: May 21, 2018
    Publication date: June 3, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Masaki ASADA, Kousuke TANI, Satonori HIGUCHI
  • Publication number: 20210147403
    Abstract: COMPOUNDS The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.
    Type: Application
    Filed: November 24, 2020
    Publication date: May 20, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Akira IMAGAWA, Takashi KONDO, Taihei NISHIYAMA, Steve COURTNEY, Chris YARNOLD, Osamu ICHIHARA, Stuart FLANAGAN
  • Publication number: 20210113568
    Abstract: The problem of the present invention is to find an effective preventive and/or therapeutic agent for an autoimmune disease, in particular, pemphigus, pemphigoid, ANCA-related angiitis and to provide the same as a medicine. The compounds having a Btk inhibitory activity to be used in the present invention inhibits antibody production from B cells and, moreover, inhibits the formation of neutrophil extracellular traps (NETs).
    Type: Application
    Filed: April 26, 2019
    Publication date: April 22, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventor: Yuko ARIZA
  • Publication number: 20210085636
    Abstract: A combination of the present invention is an effective therapy for glaucoma, in particular a combination of 2-propanyl 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butanoate and a ?-blocker, is useful as an agent for treating glaucoma since the combination enhances intraocular pressure lowering action compared to a single administration of each drug and has an effect of maintaining intraocular pressure lowering action.
    Type: Application
    Filed: December 20, 2018
    Publication date: March 25, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shinsaku YAMANE, Satoshi NAKAYAMA, Kazufumi NAGAI, Kazumi MORIYUKI, Tomohiro KARAKAWA
  • Publication number: 20210087141
    Abstract: A compound represented by the general formula (V) wherein all the symbols are as defined in the specification, has an improved balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor, and can thus serve as a therapeutic agent for S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.
    Type: Application
    Filed: February 21, 2019
    Publication date: March 25, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Toshihide WATANABE, Kensuke KUSUMI, Satomi IMAIDE, Toshimitsu ENDO, Takaki KOMIYA, Naomi TSUBURAYA